

CANADIAN CANCER TRIALS GROUP  
**GENITOURINARY CORRELATIVE SCIENCES  
TUMOUR BIOLOGY WORKING GROUP**

CHELSEA HOTEL, TORONTO, ON  
ROOM: WREN

SATURDAY APRIL 30<sup>TH</sup>, 2016, 9:00 AM – 10:00 AM

CHAIR: D. BERMAN *ON BEHALF OF R. BRISTOW*  
SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO  
STUDY COORDINATOR: ALEXANDER MONTENEGRO

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- *Appreciate the prognostic and predictive role of tissue, blood and urine biomarkers in genitourinary cancers*
- *Understand the current availability and feasibility of immunotherapy prognostic and response biomarkers in prostate cancer*
- *Appreciate the potential use of circulating tumour cells and DNA in determining the response of CRPC to novel androgen deprivation therapy regimens*

---

<b>9:00 am</b>	Welcome and Introduction.	<b>D. Berman</b>
<b>9:05 am</b>	Impact of new diagnostic categories of prostate cancer on clinical trials and correlative research	<b>T. van der Kwast</b>
<b>9:20 am</b>	Tumour Tissue Data Repository for CCTG GU trials	<b>S. Virk</b>
<b>9:30 am</b>	Current CCTG GU correlative science portfolio	<b>A. Montenegro</b>
<b>9:55 am</b>	Open forum: discussion on opportunities to enhance correlative science activity in CCTG GU trials	<b>D. Berman/ F. Vera-Badillo</b>